Your Product Innovation Begins Here: Booth 3G84

Overview


EFFEPHARM LTD

This year’s Vitafoods EU, EffePharm will showcase innovative anti-aging solutions, featuring Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand. Uthever® is pioneering the EU NOVEL FOOD application as the first NMN brand entering the risk assessment stage and is pending approval.

Also discover science-backed ingredient delivery technologies for enhanced bioavailability and functionality, featuring LipoAvail® liposomal NAD+ and liposomal Glutathione.

Download the product brochure to learn more about Uthever® NMN and check the scientific data for liposomal technology.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.